ATLANTA, Aug. 21, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the filed class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) IBRX and the upcoming August 29, 2023 Lead Plaintiff deadline. The lawsuit alleges ImmunityBio made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, good manufacturing practice (“GMP”) deficiencies at its third-party contract manufacturing organizations (“CMOs”) for its product, Anktiva; (ii) one or more of the Company’s third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies were likely to cause the FDA to reject the Anktiva Biologics License Application in its present form; and (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA.
If you bought shares of ImmunityBio between May 23, 2022 and May 10, 2023, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. [email protected] or Joshua Karr, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website www.holzerlaw.com/case/immunitybio/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is August 29, 2023.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information…